3. Function of the Core Unit as a Resource to the PEG The function of the Hematology and Clinical Chemistry Core (Core E) is to perform specific assays to accurately identify phenotypic abnormalities in the hematopoietic and metabolic functions of the genetically altered mouse strains to be studied in this PEG. Results from this Core will be recorded, analyzed, interpreted, and delivered to the Project Leaders in forms that are readily accessed and compared, such as Excel spreadsheets and common graphic files. The phenotypic data will help identify specific cell types affected and guide future experiments. In addition, where appropriate. Core E will assist in the training of each project's members, including postdoctoral fellows, in the techniques of hematology and clinical chemistry. The following screening assays will be performed on each genetically altered strain: 1. Hematology screen: Complete blood count with white cell subsets (differential count) and microscopic examination of peripheral blood smears for cellular morphology 2. Cytokine screen: a panel of acute phase and inflammatory cytokines will be measured which includes ILIA, IL1B, IL2, IL4, ILO, ILIO, ILI2, IL17A, IFNy, TNFa, G-CSF, and GM-CSF. 3. Metabolic screen: serum electrolytes, total protein, IgG immunoglobulin, liver enzymes (AST, ALT, ALP), and lipids (LDL, HDL, TG) to evaluate the overall functions of the liver, pancreas, and kidney, as well as the general metabolic status of the animal. 4. Hemostasis screen: prothrombin time (PT) and activated partial thromboblastin time (aPTT). 5. Urinary screen: pH, specific gravity, protein content, glucose, ketones, and nitrite Depending on the results of these screening tests, additional specific assays will be performed in consultation with the project leaders. In addition, depending on the specific aims of individual project, other directed functions will be performed by the Core. These functions are described under each project's Specific Aims.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-H)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Schommer, Nina N; Muto, Jun; Nizet, Victor et al. (2014) Hyaluronan breakdown contributes to immune defense against group A Streptococcus. J Biol Chem 289:26914-21
Lin, Ann E; Autran, Chloe A; Espanola, Sophia D et al. (2014) Human milk oligosaccharides protect bladder epithelial cells against uropathogenic Escherichia coli invasion and cytotoxicity. J Infect Dis 209:389-98
Mooij, H L; Cabrales, P; Bernelot Moens, S J et al. (2014) Loss of function in heparan sulfate elongation genes EXT1 and EXT 2 results in improved nitric oxide bioavailability and endothelial function. J Am Heart Assoc 3:e001274
Padler-Karavani, Vered; Hurtado-Ziola, Nancy; Chang, Yung-Chi et al. (2014) Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates. FASEB J 28:1280-93
Muto, Jun; Morioka, Yasuhide; Yamasaki, Kenshi et al. (2014) Hyaluronan digestion controls DC migration from the skin. J Clin Invest 124:1309-19
Xu, Ding; Esko, Jeffrey D (2014) Demystifying heparan sulfate-protein interactions. Annu Rev Biochem 83:129-57
Thacker, Bryan E; Xu, Ding; Lawrence, Roger et al. (2014) Heparan sulfate 3-O-sulfation: a rare modification in search of a function. Matrix Biol 35:60-72
Chang, Yung-Chi; Olson, Joshua; Beasley, Federico C et al. (2014) Group B Streptococcus engages an inhibitory Siglec through sialic acid mimicry to blunt innate immune and inflammatory responses in vivo. PLoS Pathog 10:e1003846
van Sorge, Nina M; Cole, Jason N; Kuipers, Kirsten et al. (2014) The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design. Cell Host Microbe 15:729-40
Zhang, Bing; Xiao, Wenyuan; Qiu, Hong et al. (2014) Heparan sulfate deficiency disrupts developmental angiogenesis and causes congenital diaphragmatic hernia. J Clin Invest 124:209-21

Showing the most recent 10 out of 21 publications